Triple-Negative Breast Cancer
Apr 22, 2025
FDA Approves Sanofi/Regeneron’s DUPIXENT as First New CSU Therapy in Over a Decade; Gilead’s TRODELVY + KEYTRUDA Shows PFS Benefit in PD-L1+ TNBC; Tempest’s TPST-1495 Gets FDA Orphan Tag for FAP; uniQure’s AMT-130 Granted FDA Breakthrough for Huntington’s; NeuroNOS’ BA-102 Secures FDA Orphan Status for Phelan-McDermid Syndrome
FDA Approves Sanofi/Regeneron’s DUPIXENT as First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria Regeneron Pharmaceuticals and Sanofi have announced that the FDA has approved DUPIXENT (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
